ACUTE MI- EVIDENCE-BASED THERAPY
Background:† Results of multiple randomized controlled trials are now available to dictate management of acute MI.† Despite this, in-hospital mortality from acute MI is still 15%.† Standard therapy should include 1) thrombolytics, 2) ASA, 3) Beta-blockers, 4) ACE-I.
1.†† Fibrinolytic Therapy Trialistís Collaborative Group
a.††††††††††† combined 9 RCTs, total population 58,600
b.†† IF ST elevations or BBB, 20% decr mort 0-6hrs, 13% decr mort 7-12hrs
c.†† IF ST elevations or BBB, 30% decr mort 0-1hr, 25% decr mort 2-3hrs, 18% decr mort 4-6hrs
2.†† Front-loaded tPA vs. Streptokinase (GUSTO): mortality decreased 7.4(6.9%, strokes increased 0.54(0.72%
1.†† ASA (ISIS-2, Antiplatelet Trialistsí Collaboration)
a.††††††††††† considered plt inhibitor, but likely has other mechanisms
b.†† doses 75-325mg studied
c.†† short-term benefit: 23% decr mort
d.†† long-term benefit: 31% decr reinfarction
2.†† Heparin (GUSTO, GISSI-2, ISIS-3)
a.†† binds to ATIII, deactivates IIa, Xa, IXa, XIa
b.†† no mortality benefit, increased bleed risk over ASA and thrombolyis alone
c.†† still recommended to use heparin w/ FL tPA, although no proven benefit
d.†† also used for high-risk patients with post-infarct angina
a.†† direct thrombin inhibitors
b.†† early studies (TIMI-5, 6) suggested increased patency when used with tPA compared with heparin w/o incr bleeding.† Larger studies have been complicated by excessive bleeding in both treament arms.
Beta-blockers (ISIS-1, MIAMI)
1.†† decrease HR, BP, contractility, anti-arrhythmic
2.†† doses studied: 5-15mg IV f/b 100-200mg lopressor QD
3.†† short-term: 25% decr mort in first 2 days
4.†† long-term: 25% decr mort and reinfarction
ACE-inhibitors (CONSENSUS II, GISSI-3, ISIS-4, CCS-1)
1.†† reduce afterload and preload, prevent dilation and remodeling
2.†† doses studied: captopril 6.25mg f/b 12.5-50mg TID
3.†† short-term: decr mort 6.5-12% in unselected pop
4.†† long-term: decr mort 19%, CHF 37%, recur MI 25% in high risk pop (EF<40%)
Nitrates (ISIS-4, GISSI-3)
1.†† decrease preload, afterload, dilate coronary arteries
2.†† no proven mortality benefit
3.†† reserved for high-risk patients: CHF, large anterior MI, post-infarct angina
Calcium channel blockers (TRENT, SPRINT, MDPIT, DAVIT)
1.†† decr BP, contractility
2.†† reduced risk of reinfarction, but NO mortality benefit
3.†† incr mort w/ short-acting agents
Antiarrhythmics: decr arrhythmias, but inc mortality 15-38%
Magnesium (LIMIT-2, ISIS-4): Ca antagonist, vasodilator, plt inhibitor, antiarrhythmic.† No mortality benefit.
Glucose, Insulin, Potassium: early studies suggest benefit.
Yusuf et al. European Heart Journal. 17(Suppl F): 16-29, 1996.